Will MONARCH MASH Phase 2b hit its primary endpoint by year-end 2026?
Current Prediction
Why This Question Matters
MONARCH MASH Phase 2b is the first pipeline program beyond Lifyorli where a primary endpoint readout is expected by end of 2026. A positive readout would validate the SGRA platform extension into a multi-billion-dollar indication (MASH), improving DEFENSIBLE toward DOMINANT and resolving UNDERPRICED. A failure would not invalidate the thesis (miricorilant is an optional indication expansion, not the base case) but would narrow the pipeline option value the market already prices at near-zero. Informative asymmetric bet.
Prediction Distribution
Individual Predictions(9 runs)
Decomposition: P(MONARCH reads out by 2026-12-31) * P(primary endpoint hit | readout) * P(clean safety | readout). (1) Readout timing: management guided 'end of 2026' but MASH trial data delivery historically slips 2-4 months from guidance; probability of YE 2026 readout ~0.55-0.65. (2) Primary endpoint hit: Phase 2b MASH base rate is 35-50%; miricorilant liver-potent mechanism is sound but unproven in Phase 3-readout-scale trial; SGRA mechanism has produced positive Cushing's, ALS, ovarian signals, supporting ~45-55% conditional probability. (3) Clean safety: SGRA class has shown ALT elevation as known side effect in Cushing's population; MASH trials (liver patients) are particularly sensitive to ALT elevation; probability ~65-75%. Joint: 0.60 * 0.50 * 0.70 = 0.21. Slight upside adjustment for pre-enrollment signal validation: 0.28.
MASH Phase 2b endpoint hit rate is genuinely low in this era (post-resmetirom approval, most near-entrants fail primary endpoint or struggle with composite endpoints). Competitive landscape is crowded and bar is higher. Miricorilant has a liver-potent mechanism differentiation but its Phase 2a signal was not conclusively strong. Add timing slippage risk (end-of-2026 guidance is ambitious for MASH trials with imaging endpoints requiring long follow-up) and clean-safety requirement, probability is ~0.25. The strict 'clean safety' requirement particularly concerns me - any ALT elevation signal, even below concerning thresholds, could trigger 'not clean' classification.
Corcept has strong pipeline execution track record: DAZALS hit in ALS (84% reduction in risk of death), Lifyorli approved 4 months early. This 'execution signal' is worth ~10pp on the conditional probability. Management's end-of-2026 timing was given at Q4 2025 earnings - 12 months of warning before the deadline suggests actual confidence. Combined with mechanism soundness (liver-potent SGRA for liver fibrosis makes biological sense), conditional probability can reach 0.40-0.45. Timing slippage risk remains ~20-25%. Joint: 0.75 * 0.45 = 0.34. Probability 0.33.
MASH Phase 2b primary endpoint hit rate ~35-45%. Corcept execution track record adds ~5pp. Timing slippage risk ~25%. Clean safety requirement filters 20-30%. Joint: ~30% * 0.75 = 0.23. Some upside adjustment for pre-enrollment positive indicators = 0.28.
Weighting the factors: (1) fully enrolled trial = timing certainty higher than typical, (2) miricorilant Phase 2a data did show positive liver signals even if not definitive, (3) Corcept has delivered on previous trial guidance, (4) SGRA class has produced multiple positive trials (Cushing's, ALS). Probability ~0.32.
MASH is a challenging indication with a crowded competitive field (resmetirom approved, multiple GLP-1 and FGF21 programs). Phase 2b success bar is relatively high. SGRA class ALT concern in liver population adds safety filter risk. Timing slippage historically 2-4 months for MASH trials. Net: 0.25.
MASH Phase 2b base rate ~35-45% hit. Timing slippage risk ~20-25%. Clean safety filter. Corcept execution track record positive. Probability 0.30.
MASH trials challenging, crowded field, SGRA class ALT concern. Joint probability low. Settle at 0.25.
Fully enrolled = timing anchor. Corcept track record. SGRA mechanism extension to MASH plausible. Phase 2b hit probability ~40-45% conditional on readout, adjusted down for timing and safety filters. Probability 0.30.
Resolution Criteria
Resolves YES if by 2026-12-31 Corcept files an 8-K or issues a press release reporting MONARCH MASH Phase 2b top-line data where (a) the pre-specified primary endpoint achieves statistical significance (p<0.05), AND (b) no material safety concerns are disclosed (no drug-induced liver injury above background, no serious adverse event signal leading to hold). Resolves NO if (a) top-line data is reported and the primary endpoint is not met, OR (b) a safety hold or adverse finding is disclosed, OR (c) no top-line data is reported by 2026-12-31 (on the grounds that end-of-2026 guidance is the management commitment and slippage is information).
Resolution Source
CORT 8-K filings, press releases, or investor presentations disclosing MONARCH Phase 2b top-line data
Source Trigger
MONARCH MASH Phase 2b primary endpoint readout by 2026-12-31 reports primary endpoint hit with clean safety
Full multi-lens equity analysis